Home > Products > Biosimilars

BioSIM anti-Human PD-1/CD279 Antibody (Tislelizumab Biosimilar), Research Grade

Catalog: SIM0441
Cost advantage to: SIM0038
Product Details Specifications Application References Related Products

Product Details

This non-therapeutic biosimilar, using Tislelizumab’s variable regions, is ideal for research. It binds human PD-1 (CD279, a 50-55 kDa receptor regulating T-cell activation/peripheral tolerance). PD-L1 overexpression in tumors reduces CD8 T-cell lysis. Structurally modified Tislelizumab has high PD-1 affinity (Kd 0.15nmol/L), >90% PD-1 occupancy at 5mg/kg, and preliminary anti-solid tumor effects.
 

Specifications

Product Name BioSIM anti-Human PD-1/CD279 Antibody (Tislelizumab Biosimilar), Research Grade
Size 1mg/5mg
Isotype /
Target PD-1/CD279
Other Names BGB-A317, CAS: 1858168-59-8
CAS 1858168-59-8
Reactivity Human
Host Species Humanized
Background This non-therapeutic biosimilar, using Tislelizumab’s variable regions, is ideal for research. It binds human PD-1 (CD279, a 50-55 kDa receptor regulating T-cell activation/peripheral tolerance). PD-L1 overexpression in tumors reduces CD8 T-cell lysis. Structurally modified Tislelizumab has high PD-1 affinity (Kd 0.15nmol/L), >90% PD-1 occupancy at 5mg/kg, and preliminary anti-solid tumor effects.
Applications ELISA, FACS, Functional assay, Research in vivo
Purification Protein A/G
Storage To ensure appropriate storage, Please avoid repeated freeze thaw cycles. Keep the product at 4°C for short-term needs (1–2 weeks); Store at -20°C for up to 12 months.  For long-term storage, store at -80°C.
Shipping 2-8°C with blue ice
Concentration Lot specific, generally ≥ 5.0 mg/ml
Shelf Life 12 months from the date of receipt if stored as recommended
Formulation PBS, pH 7.4, contains no stabilizers or preservatives
Sterility 0.2 μM filtered
Endotoxin ≤ 1.0 EU/mg
Purity 99%

Application References

Related Products